Tobracid Dm 3 Gm Tablets (Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment): Clinical Profile, Uses, Dosage, and Safety

Tobracid Dm 3 Gm Tablets is a prescription product containing Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment. It is used in clinically selected treatment pathways and should be used only under professional supervision. This page summarizes core product facts to support informed discussions with licensed healthcare professionals.

Safe use depends on diagnosis, formulation, route, dose, and duration. For this reason, the sections below provide a structured profile aligned with clinical documentation standards for pharmaceutical education.

Introduction

Tobracid Dm 3 Gm Tablets is a ophthalmic solution manufactured by Entod Pharmaceuticals Ltd . Specifically designed for the management of steroid-r. It is commonly positioned within the antibiotic class and is typically prescribed for clearly defined therapeutic use cases. While product names are familiar to patients, treatment decisions should always be guided by clinical evaluation and official labeling.

Patients should verify product identity, strength, and route every time a medicine is dispensed. Similar-looking brand names can represent different active ingredients, and substitutions should only be made with clinician or pharmacist confirmation.

1. Product Overview / Clinical Profile

• Brand Name: Tobracid Dm 3 Gm Tablets
• Active Ingredient: Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment
• Manufacturer: Entod Pharmaceuticals Ltd . Specifically designed for the management of steroid-r
• Dosage Form: ophthalmic solution
• Therapeutic Category: antibiotic

2. Mechanism of Action (MOA)

Tobracid Dm 3 Gm Tablets acts through Tobramycin 0.3% & Dexamethasone 0.1% w/w Ophthalmic Ointment, an antibacterial mechanism that inhibits critical microbial growth pathways and supports clearance of susceptible infections when used at the prescribed dose and duration.

Mechanistic understanding helps explain prescribing rationale, expected response timelines, and monitoring requirements. For antimicrobials, susceptibility patterns and resistance risk are central. For ocular pressure therapies, durable adherence and pressure control trends matter more than short-term symptom fluctuations. For anti-inflammatory and other chronic-use medicines, risk-benefit is reassessed through follow-up.

MOA should always be interpreted in context: pharmacology defines potential effect, but real-world response depends on diagnosis quality, adherence, interacting medicines, and patient-specific comorbid conditions.

3. Therapeutic Indications

Tobracid Dm 3 Gm Tablets is typically used for bacterial conjunctivitis and related susceptible ocular infections. Final indication should match local labeling, clinician judgement, and patient-specific risk profile.

• Use only for the indication selected by a licensed prescriber.
• Avoid self-initiating or extending treatment duration without clinical review.
• Reassessment is needed if expected improvement does not occur.

Clinical teams often adjust treatment based on severity, prior therapy exposure, and response monitoring. The objective is to achieve therapeutic benefit while minimizing avoidable adverse events.

4. Dosage and Administration

General dosing guidance: 3 mg (0, or as directed by the prescriber.

Exact schedules vary by diagnosis and patient profile. Prescribed instructions on label frequency, duration, and technique should be followed precisely.

• Use exactly as directed by the prescriber.
• Do not skip doses or double up missed doses unless advised.
• If ophthalmic, avoid touching the dropper/tube tip to any surface.
• If injectable, follow sterile handling and storage requirements.
• Ask the clinician for written missed-dose guidance at initiation.

Administration quality can materially affect outcomes. Correct timing, route, and storage are often as important as selecting the correct medicine class.

5. Safety Profile and Precautions

Adverse effect profiles vary by active ingredient and class. Patients should review contraindications, allergy history, organ-function concerns, and interaction risks before first use. Persistent, severe, or unexpected symptoms require prompt medical review.

Important precautions include adherence to prescribed duration, avoiding unsupervised dose escalation, and reporting lack of response early. For ophthalmic products, hygiene and contamination control are critical. For systemic agents, clinicians may require lab monitoring depending on risk factors.

Immediately seek urgent care for signs of severe hypersensitivity, breathing difficulty, progressive swelling, sudden vision changes, or other acute deterioration.

Storage and Handling

Store according to official product labeling. Keep medicines in original packaging, away from heat and moisture, and out of reach of children. Ophthalmic products should remain capped and contamination-free; injectables may require strict temperature control.

Discard expired or compromised products. If a container appears damaged, use should be deferred until a pharmacist or clinician confirms suitability.

Clinical Follow-up and Counseling Points

Follow-up should assess clinical response, tolerance, and adherence. Patients should be encouraged to keep a medication list, disclose over-the-counter use, and communicate treatment changes between providers. Counseling should reinforce that this information is educational and does not replace individualized diagnosis.

Where relevant, clinicians may align therapy with local antimicrobial stewardship, chronic disease protocols, or specialty pathways to preserve efficacy and reduce avoidable risk.